Today there is no cure for Multiple Sclerosis (“MS”)

Today there is no cure for Depression.

FSD Pharmaceuticals is working to change that.

Pipeline of Clinical Candidates Addressing

Multibillion-Dollar Markets



A psychoactive molecule for the

treatment of neuropsychiatric

disorders currently undergoing IND-enabling studies



A patented neuroprotective NCE

shown to prevent and reverse

myelin degradation, the underlying

cause of multiple sclerosis, in

preclinical models. Currently

undergoing IND enabling studies



A proprietary anti-inflammatory

product completed phase-1

clinical trials with excellent safety

profile, and is under evaluation for

a suitable indication to launch

phase-2 clinical trials

The Psychedelics Market Opportunity (Lucid-PSYCH)

Growing body of research suggests Psychedelics have the potential to treat a variety of

neuropsychiatric disorders such as PTSD, depression, specifically complex TRD and MDD,

and anxiety

  • FDA approval of SPRAVATO® (esketamine) for treatment-resistant depression
  • Promising Ph2 clinical data on MDMA-assisted psychotherapy for PTSD treatment
  • Expanding pipeline of psychedelic-based therapies

Millions of people suffer from mental illness each year;

representing a multi-billion dollar opportunity

FSD sees a significant opportunity in

becoming an early mover in developing psychedelic assets.

The global anxiety disorders and

depression treatment market size was

valued at US$15.2B in 2015

Psychedelics market for mental Illness:

CAGR of 16.3% during 2020–27 and

expected to reach US$6.9 Billion by

2027 from $2.0 Billion in 20194

FSD Pharma Differentiation (Lucid-PSYCH)

Development Stage


Target Condition

Mental health and neurodegenerative conditions

Proprietary Molecules


Time to Market

5-8 Years



Market Access Strategy

Multiple Entry Points

Acquisition Of Lucid

Psycheceuticals Inc. “Lucid”

With this transaction comes exciting new additions to our biotechnology pipeline, representing what we believe to be a major step toward fulfilling their mission of the most promising treatments for TOTAL BRAIN HEALTH

Working with excellent minds in medicine and science at the University Health Network (UHN), the largest health research organization in Canada, they are focused on developing cutting-edge therapies for some of the hardest-to-treat diseases.

If you have a loved one or friend suffering with MS, you know the challenges they face today with current treatments and medicine. Similarly, if you are close to someone struggling with Depression, you know how hard it can be for them and their caregivers to find effective therapies. Even worse, MS can often cause Depression and Anxiety.

How Lucid Acquisition Immediately Expands FSD-PEA Biotech Pipeline

Lucid has developed two unique drug candidates, which are complementary to our existing FSD-PEA (also known as FSD-201) drug candidate:
  1. Lucid0MS for the treatment of MS.
  2. LUCID-Psych targeting Depression.

Lucid-MS is a patented new chemical entity (meaning it is new and has never been used before) for MS that was developed over many years by doctors, scientists and researchers at the UHN. Lucid recently exclusively licensed Lucid-MS from the UHN.

Over USD $54.1 Million current assets on the balance sheet as of June 30, 2021

FSD PHARMA (“HUGE”) intends to approach brain disorders and treat them in a totally different unique manner called TOTAL BRAIN HEALTH

Why Is This Important?

FSD believes all approved MS drugs today have been designed to target the immune system in one way or another because the general view in the medical world has been that MS is an autoimmune disease.

The Lucid scientific team thinks differently. They believe that therapeutic applications involving Lucid-MS could be disease modifying by possibly reversing and protecting neurodegeneration without interacting with the immune system.

What does this mean?

Strong Company Leadership

Recent changes in leadership structure and acquisitions have made

Anthony Durkacz

Founder, Interim CEO & Executive Co-Chairman of the Board


Founder, President & Executive Co-Chairman of the Board


Chief Financial Officer


Co-Founder of Prismic Pharmaceuticals


Senior Vice-President


CEO of Lucid




199 Bay St.

Suite 4000

Toronto, ON, M5L 1A9



Legal Disclaimer

Guerilla Stocks is a project of Dadmin Capital LLC and intended solely for entertainment and informational purposes. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/

This website / media webpage is owned, operated and edited by Dadmin Capital LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “Dadmin” refers to Dadmin Capital LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. Dadmin business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors

We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Dadmin often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

Social Media Outlet Compensation